Athlete's Foot (clotrimazole)
Topical Antifungals Topical Cream (Gram)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Clotrimazole, an imidazole derivative, is a synthetic azole antifungal agent.
Clotrimazole is a broad-spectrum antifungal agent that exerts its antifungal activity by interfering with the biosynthesis of ergosterol, a major component of the fungal cell membrane. As a result, cell membrane permeability is altered, causing loss of potassium and other cellular constituents. Ergosterol also plays a role in directly stimulating the growth of fungal cells.
The combined effects of these actions result in a dose- and time-dependent inhibition of fungal growth.
Clotrimazole is generally considered to be fungistatic, but exhibits fungicidal effects at higher concentrations. In vitro, clotrimazole exhibits fungistatic and fungicidal activity against most strains of Trichophyton rubrum, T. mentagrophytes, Epidermophyton floccosum, and Microsporum canis, and Candida species including Candida albicans. In general, the in vitro activity of clotrimazole corresponds to that of tolnaftate and griseofulvin against the mycelia of dermatophytes (Trichophyton, Microsporum, and Epidermophyton), and to that of the polyenes (amphotericin B and nystatin) against Candida.
Resistance to clotrimazole has been observed in some Candida isolates, particularly in immunocompromised patients, and has been linked to overexpression of efflux pump genes. Cross resistance can occur among the azole antifungals (e.g., clotrimazole, ketoconazole, miconazole).
Following oral administration of a lozenge containing 10 mg of clotrimazole and dissolution of the lozenge in the mouth (which takes approximately 30 minutes), concentrations of clotrimazole sufficient to inhibit most species of Candida are present in saliva for up to 3 hours. Administration of a 10-mg clotrimazole lozenge every 3 hours reportedly maintains salivary concentrations of clotrimazole greater than the MIC of the drug for most species of Candida. The long-term effective concentration of clotrimazole in saliva appears to be related to slow release of the drug from the oral mucosa to which the drug is apparently bound.
The total amount of clotrimazole absorbed following dissolution in the mouth of a lozenge containing the drug has not been determined to date.
Following topical and vaginal administration, clotrimazole appears to be minimally absorbed. Following application to the skin, the highest concentrations of clotrimazole are present in the stratum corneum; lower drug concentrations occur in the stratum spinosum and the papillary and reticular dermis.
USES: Clotrimazole is used to treat skin infections such as athlete's foot, jock itch, ringworm, and other fungal skin infections (candidiasis). This medication is also used to treat a skin condition known as pityriasis (tinea versicolor), a fungal infection that causes a lightening or darkening of the skin of the neck, chest, arms, or legs. Clotrimazole is an azole antifungal that works by preventing the growth of fungus.
Generic name: clotrimazole
Pronunciation: (kloe-TRIM-a-zole)
Drug class: Topical Antifungals
Therapeutic class: Dermatological
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Athlete's Foot
Indications
The following indications are listed for Athlete's Foot:
- Cutaneous Candidiasis
- Diaper Rash
- Tinea Corporis
- Tinea Cruris
- Tinea Pedis
- Tinea Versicolor
Also known as: Corporeal Ringworm, Cutaneous Candidosis, Cutaneous Moniliasis, Dermatomycosis Pedis, Dhobie Itch, Diaper Dermatitis, Eczema Marginatum, Jock Itch, Pityriasis Versicolor, Tinea Circinata, Tinea Furfuracea, Tinea Glabrosa, Tinea Inguinalis, Tinea Of The Foot.
Dosing
No dosing information is available for this tab.
Clotrimazole is administered topically to the oropharyngeal area as an oral lozenge, to the skin as a cream or solution, or intravaginally as a vaginal cream.
The topical cream and solution are not intended for ophthalmic use.
Clotrimazole also is available in fixed combination with betamethasone dipropionate as a cream or lotion; see prescribing information for the combination product for additional details.
Store clotrimazole oral lozenges, topical cream, and topical solution at 20--25degreesC. Avoid freezing oral lozenges.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Ft Athlete's Foot 1% Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route 2 times per day in the morning and evening. |
| Ft Athlete's Foot 1% Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route once daily. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| Clotrimazole 1% Topical Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route 2 times per day in the morning and evening. |
| Terbinafine 1% Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route once daily. |
| Eq Terbinafine 1% Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route once daily. |
| Cvs Clotrimazole 1% Top Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route 2 times per day in the morning and evening. |
| Butenafine Hcl 1% Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route once daily. |
| Cvs Butenafine Hcl 1% Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route once daily. |
| Tm-Clotrimazole 1% Top Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route 2 times per day in the morning and evening. |
| Qc Clotrimazole 1% Top Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route 2 times per day in the morning and evening. |
| Gnp Terbinafine 1% Cream | Maintenance | Apply to the affected and surrounding areas of skin by topical route once daily. |
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
*Known hypersensitivity to clotrimazole or other imidazoles or any ingredient in the formulation.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- No disease contraindications
Adverse reactions
Lozenge: nausea, vomiting, unpleasant mouth sensations, and pruritus.
Topical cream or solution: blistering, erythema, edema, pruritus, burning, stinging, peeling, urticaria, and general irritation of skin.
Rare or Very Rare
- Abnormal desquamation
- Anaphylaxis
- Angioedema
- Blistering skin
- Blistering skin
- Blistering skin
- Dermatitis due to topical drug
- Dyspnea
- Edema
- Erythema
- Erythema
- Hypersensitivity drug reaction
- Hypersensitivity drug reaction
- Hypotension
- Paresthesia
- Pruritus of skin
- Pruritus of skin
- Pruritus of skin
- Skin inflammation
- Skin irritation
- Skin irritation
- Skin irritation
- Skin rash
- Stinging of skin
- Syncope
- Urticaria
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy of clotrimazole lozenges have not been established in children <3 years of age. Safety and efficacy of prophylactic therapy with clotrimazole lozenges have not been established in children.
Clotrimazole topical cream or solution is not recommended for self-medication in children <3 years of age.
Clotrimazole vaginal cream is not recommended for self-medication in children <12 years of age.
Preparations containing clotrimazole in fixed combination with betamethasone dipropionate are not recommended for use in children <17 years of age or for diaper dermatitis.
There are no adequate and controlled studies of clotrimazole lozenges in pregnant women; the drug should be used during pregnancy only if the potential benefits justify the potential risks to the fetus. In clinical trials, use of intravaginal clotrimazole in pregnant women in the second and third trimester was not associated with adverse effects; there are no adequate and well-controlled studies in pregnant women in the first trimester. .
In animal reproductive studies, clotrimazole demonstrated embryotoxic effects, but was not teratogenic when given in doses significantly higher than the recommended human dose.
It is not known whether clotrimazole is excreted in human milk, caution should be exercised when the drug is used in nursing woman.
There were an insufficient number of patients >=65 years of age in clinical studies of clotrimazole lozenges to determine whether geriatric patients respond differently from younger patients; other reported experience did not find any differences in response between these patients.
ICD codes
| Code | Type | Description |
|---|---|---|
| Cutaneous candidiasis | ||
| B37.2 | ICD10CM | Candidiasis of skin and nail |
| Diaper rash | ||
| L22 | ICD10CM | Diaper dermatitis |
| Tinea corporis | ||
| B35.4 | ICD10CM | Tinea corporis |
| Tinea cruris | ||
| B35.6 | ICD10CM | Tinea cruris |
| Tinea pedis | ||
| B35.3 | ICD10CM | Tinea pedis |
| Tinea versicolor | ||
| B36.0 | ICD10CM | Pityriasis versicolor |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.